Michael Calore

Michael Calore is a senior editor at WIRED, where he oversees consumer products coverage in print and online. He also hosts the weekly Gadget Lab podcast. As a writer, he covers various topics including music, film, art, software, social media and underground culture. His work can be found on WIRED's website and through his Instagram.

Biography:  https://www.wired.com/author/michael-calore/

99%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This author is known for its high journalistic standards. The author strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. The author has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

85%

Examples:

  • GLP-1 drugs are easy to procure from telehealth providers even with false information.
  • GLP-1 medications like Ozempic are in high demand.
  • Ozempic is a well-known GLP-1 medication that helps regulate appetite, digestion, and blood sugar.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

New Study Shows Tirzepatide Outperforms Semaglutide for Weight Loss, but Combination with Very Low-Calorie Diet Yields Best Results for Diabetes Treatment

New Study Shows Tirzepatide Outperforms Semaglutide for Weight Loss, but Combination with Very Low-Calorie Diet Yields Best Results for Diabetes Treatment

Broke On: Sunday, 14 July 2024 New research suggests Tirzepatide, the active ingredient in Mounjaro and Zepbound, is more effective for weight loss than semaglutide. Both GLP-1 receptor agonists reduce appetite and improve diabetes treatment when used with very low-calorie diets. However, drug shortages and emergence of clones raise concerns over regulation.